A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Study Summary

The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.

Conditions

Myelofibrosis Moderate Thrombocytopenia Mild Thrombocytopenia

Interventions / Drugs

Selinexor 60 mg Selinexor 40 mg Ruxolitinib Pacritinib Momelotinib

View on ClinicalTrials.gov ↗

Sponsor

KPTI

Karyopharm Therapeutics

Oncology

D40/100

Study Details

Enrollment58 participants

Primary Completion—

Lead SponsorKaryopharm Therapeutics Inc

Data Retrieved2026-04-11 04:19:01.923383+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.